Biologic treatment in Sjögren's syndrome

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Sjogren's syndrome (SS) is a chronic systemic autoimmune disease impacting exocrine glands.
• SS presents with diverse symptoms, including constitutional and extraglandular manifestations.
• Current treatments primarily focus on symptom management, with limited evidence for conventional immunosuppressants.

Purpose of the Study:

• To review the efficacy of biologic treatments for Sjogren's syndrome.
• To discuss emerging therapies targeting key pathways in SS pathogenesis.
• To highlight the need for multidisciplinary approaches in managing SS.

Main Methods:

• Literature review of existing evidence on biologic therapies for SS.
• Analysis of studies investigating B cell-targeted agents (rituximab, epratuzumab, belimumab).
• Evaluation of early-phase studies on T cell inhibition (abatacept, alefacept) and other molecular targets (IFN, IL-6, Toll-like receptor).

Main Results:

• Biologic agents targeting B cells have shown promising, though variable, results in SS treatment.
• Inhibition of T cell stimulation represents another potential therapeutic avenue.
• Ongoing research explores modulation of IFN, IL-6, and Toll-like receptors.

Conclusions:

• Systemic drugs can effectively control extraglandular manifestations of SS.
• Biologic therapies offer potential for more targeted and effective SS treatment.
• Further research is crucial to validate findings and optimize treatment strategies for SS.